Reuters UKAstraZeneca Boosts Pipeline with $232 Million Synairgen DealZacks.comAstraZeneca (AZN – Analyst Report) announced that it has entered into an agreement with UK-based Synairgen to in-license its respiratory disease candidate, SNG001. SNG001 is being developed for the treatment of respiratory tract viral infections in patients …AstraZeneca enters into $232m asthma drug deal with SynairgenPharmaceutical Business ReviewAstraZeneca takes breath and splashes out on asthma remedyThe Times (subscription)Astrazeneca buys licence for new anti-asthma treatmentCITY A.M.Express.co.uk -This is Money -Reutersall 52 news articles …Read Full Story
AstraZeneca Boosts Pipeline with $232 Million Synairgen Deal - Zacks.com
Real Estate of Cebu
